Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 6/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.89 |
| ▸ | TSHR | P16473 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 3/20 | 0.89 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | CASP1 | P29466 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | PKLR | P30613 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483657 | 1.00 | PKM (0.89) | PKMKMT2ATSHRMEN1MCOLN3 | |
| SCHEMBL18134604 | 0.88 | MCOLN3 (0.83) | PKMKMT2ATSHRMEN1MCOLN3 | |
| SCHEMBL3169939 | 0.85 | MCOLN3 (0.97) | PKMKMT2ATSHRMEN1MCOLN3 | |
| SCHEMBL3814970 | 0.83 | MCOLN3 (1.00) | PKMKMT2ATSHRMEN1MCOLN3 | |
| SCHEMBL30821997 | 0.83 | MCOLN3 (1.00) | PKMKMT2ATSHRMEN1MCOLN3 | |
| SCHEMBL8062135 | 0.82 | KMT2A (0.63) | PKMKMT2ATSHRMEN1KDM4E | |
| SCHEMBL10167567 | 0.81 | TSHR (0.61) | PKMKMT2ATSHRMEN1KDM4E | |
| SCHEMBL8064667 | 0.81 | KMT2A (0.61) | PKMKMT2ATSHRMEN1KDM4E | |
| SCHEMBL15014129 | 0.81 | PKM (0.89) | PKMKMT2ATSHRMEN1MCOLN3 | |
| SCHEMBL12655865 | 0.81 | MCOLN3 (0.71) | PKMKMT2ATSHRMEN1MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | LDLR, APOB, NR1H2 | PKM 4241/4885KMT2A 4002/4885TSHR 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.